Merck says tulisokibart hits primary endpoint in Phase 2b hidradenitis suppurativa trial

Merck said it plans to move tulisokibart into Phase 3 in hidradenitis suppurativa after first Phase 2b results met the main efficacy goal. Safety was broadly comparable with placebo, and the anti-TL1A program would expand beyond inflammatory bowel disease.